ACT Brief: Clinical Trial Trends and 2026 Outlook, AI Agents and Workforce Transformation, and Degrader-Antibody Conjugate Partnership

Apr 13, 10:00 AM
Headliner
Share
Subscribe
In today's ACT Brief, we explore industry perspectives on operational and methodological shifts defining 2026, how agentic AI will augment clinical trial roles over the next two years, and Roche's expanded partnership with C4 Therapeutics on next-generation antibody conjugates.
Share
Subscribe
Next
ACT Brief: Real-World Data Access Expansion, eSource Implementation at Scale, and FDA Regulatory Setback for Oncolytic Therapy
Top episodes
AI in Clinical Trials - A Long, But Promising Road Ahead
by Applied Clinical Trials
Unifying Industry to Better Understand GCP Guidance
by Applied Clinical Trials
Diversity in Clinical Trials: The Need to Take Action
by Applied Clinical Trials